Delivery Order SPE2DR25D1053-SPE2DR26FT335
- Not listed
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 25, 2025, for the supply of Ozempic 2 mg/dose (8 mg/3 ml) 3 ml vials, with a contract ceiling value of $5,010.26. This is a firm fixed price delivery order with an ultimate completion date of August 26, 2025, and represents a non-set-aside competitive award. The pharmaceutical product will be performed at AmerisourceBergen's facility in Conshohocken, Pennsylvania, where the company maintains its...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 26, 2025, for the supply of Ozempic 1 mg/dose (4 mg/3 mL) in 3 mL vials, with a ceiling value of $8,146.58 and an ultimate completion date of September 29, 2025. This firm fixed-price delivery order was competitively awarded with no set-aside designation and represents a continuation of AmerisourceBergen's pharmaceutical supply services under the Defense Logistics Agency's Medical Supply Chain...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for $11,833.28 on October 27, 2025, for the supply of Ozempic 2 mg/dose (8 mg/3 mL) in 3 mL vials, with completion scheduled for October 28, 2025. The contract utilizes firm fixed-price pricing and carries no set-aside designation, indicating it was competitively awarded. The place of performance is located in Conshohocken, Pennsylvania, where AmerisourceBergen maintains its corporate headquarters. This delivery...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 26, 2025, for the supply of Ozempic 1 mg/dose (4 mg/3 mL) in 3 mL vials, with a ceiling value of $3,759.96. This competitively awarded, firm fixed-price delivery order is scheduled for completion by August 27, 2025, with performance at AmerisourceBergen's Conshohocken, Pennsylvania facility. The contract represents a small-value transaction typical of the company's regular medical supply deliveries...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 4, 2025, for the supply of Ozempic 1 mg/dose (4 mg/3 mL) in 3 mL vials, with a ceiling value of $42,011.63. This firm fixed-price delivery order, which is set to be completed by August 5, 2025, will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The award represents a routine pharmaceutical procurement within the Defense Logistics Agency's medical supply...
- The Defense Logistics Agency awarded a delivery order valued at $5,689.24 to AmerisourceBergen Drug Corp on September 15, 2025, for the supply of Ozempic 1 mg/dose (4 mg/3 ml) 3ml vials. This is a firm fixed-price, non-set-aside contract with an ultimate completion date of September 16, 2025, and performance at the contractor's facility in Conshohocken, Pennsylvania. The delivery order represents a small-value transaction within AmerisourceBergen's broader federal pharmaceutical supply...
- The Defense Logistics Agency awarded a delivery order valued at $3,633.25 to AmerisourceBergen Drug Corp on August 7, 2025, for the supply of Ozempic 1 mg/dose (4 mg/3 mL) in 3 mL vials. The contract utilizes a firm fixed price arrangement with an ultimate completion date of August 8, 2025, and carries no set-aside designation, indicating it was competitively awarded. Performance will occur at AmerisourceBergen's Corporate Office location in Conshohocken, Pennsylvania. This delivery order is...
- The Defense Logistics Agency awarded a $13,908.48 delivery order to AmerisourceBergen Drug Corp for Ozempic 1 mg/dose (4 mg/3 ml) 3 ml vials on July 22, 2025, with completion scheduled for July 23, 2025. This is a firm fixed price delivery order with no set-aside designation, meaning it was competitively awarded. The pharmaceutical product will be delivered to AmerisourceBergen's place of performance in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's larger...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 18, 2025, for the supply of Ozempic 2 mg/dose (8 mg/3 mL) in 3 mL vials, with a ceiling value of $4,552.06. This is a firm fixed-price delivery order with an ultimate completion date of September 19, 2025, and represents a competitively awarded, non-set-aside contract. The order will be fulfilled from AmerisourceBergen's Corporate Office location in Conshohocken, Pennsylvania. This delivery order is...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 26, 2025, for the supply of Ozempic 1 mg/dose (4 mg/3 mL) in 3 mL vials, with a ceiling value of $1,636.87. This competitively awarded, firm fixed-price delivery order is scheduled for completion by August 27, 2025, and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The contract represents a continuation of pharmaceutical supply support to federal...
- SPE2DR25D1053Indefinite Delivery Contract
- SPE2DR25D1053-SPE2DR26FT335Delivery Order
The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on October 27, 2025, for the supply of Ozempic 1 mg/dose (4 mg/3 ml) 3ml vials, with a ceiling value of $25,429.50 and ultimate completion date of October 28, 2025. This is a firm fixed price delivery order with no set-aside designation, issued under AmerisourceBergen's competitive, non-set-aside contract vehicle. The pharmaceutical product will be delivered to the company's place of performance in Conshohocken, Pennsylvania, where AmerisourceBergen maintains its corporate headquarters as a major pharmaceutical distributor serving federal medical procurement needs. This delivery order represents a routine pharmaceutical procurement supporting military and federal healthcare systems. AmerisourceBergen holds a significant Indefinite Delivery Contract (IDC) with DLA Troop Support Medical valued at $999,999,999.00 through December 2026, which serves as the overarching vehicle for such deliveries. The company's federal contract portfolio demonstrates extensive experience supplying a comprehensive range of pharmaceutical products, including specialty medications, vaccines, and medical supplies across multiple therapeutic domains to support Defense Health Agency operations and other federal healthcare customers worldwide.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $25.4k | 10/27/25 |